Guang-hai Dai
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
First-In-Human [177Lu]Lu-FAPI-XT Therapy Combined With Anti-PD-1 Antibody in a Patient With Metastatic Colon Cancer Who Has Progressed on Multiple Prior Lines of Therapy.
Journal: JCO precision oncology
Published: July 10, 2026
First-Line Tislelizumab Combined with Bevacizumab and CAPOX for Metastatic Gastroesophageal Adenocarcinoma with Low Programmed Death-Ligand 1 Expression.
Journal: Cancer communications (London, England)
Published: November 07, 2025
Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?
Journal: World journal of clinical oncology
Published: March 28, 2022
A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX).
Journal: Journal of cancer research and clinical oncology
Published: February 05, 2021
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 25, 2021
Lysyl oxidase and hypoxia-inducible factor 1α: biomarkers of gastric cancer.
Journal: World journal of gastroenterology
Published: January 19, 2019
Overexpression of c-kit(CD117), relevant with microvessel density, is an independent survival prognostic factor for patients with HBV-related hepatocellular carcinoma.
Journal: OncoTargets and therapy
Published: March 23, 2018
Decreased spinal endomorphin-2 contributes to mechanical allodynia in streptozotocin-induced diabetic rats.
Journal: Neurochemistry international
Published: March 02, 2017
Leucine-rich alpha-2-glycoprotein-1, relevant with microvessel density, is an independent survival prognostic factor for stage III colorectal cancer patients: a retrospective analysis.
Journal: Oncotarget
Published: December 07, 2016
Retraction notice to "Antinociceptive effects of endomorphin-2: Suppression of substance P release in the inflammatory pain model rat".
Journal: Neurochemistry international
Published: June 10, 2016
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
Journal: Clinical colorectal cancer
Published: March 02, 2016
Last Updated: 09/26/2026